Search the Newsreel

Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript

This article provides the transcript for Altimmune Inc.'s RECLAIM Phase 2 Trial in AUD Topline Results Conference Call held on July 28, 2026. The call began with an introduction by Louis Sine, Vice President of Investor Relations, and detailed how participants could ask questions. …

Bitmine Immersion Technologies (BMNR) Stock Could Be A Bargain On Book Value But Weak On Broader Checks

Immunome (IMNM) Expected to Post Earnings on Wednesday

Zimmer Biomet (ZBH) to Post Earnings on Wednesday

Immunitybio Inc (IBRX) Institutional Confidence

Immunitybio Inc (IBRX) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 20.71%, marking a 32.91% increase quarter-over-quarter. Paul Tudor Jones is the largest institutional shareholder, holding 557.67K shares.

IMUX|Immunic Inc|Price:13.271|Chg%:-0.539

This article provides a detailed stock analysis of Immunic Inc (IMUX) based on TradingKey's comprehensive stock score. It highlights Immunic's strong fundamentals and high growth potential, noting it's fairly valued within the Biotechnology & Medical Research industry. The analysis also covers high institutional ownership …

AC Immune SA (ACIU) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for AC Immune SA (ACIU), noting its current risk score of 1.90 and ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 1.61, indicating higher volatility compared to the S&P 500, and …

Immatics NV (IMTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immatics NV (IMTX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. As of the analysis, the stock trades between support at 7.64 and resistance at 10.36, with a current price …

Form 4 Lyell Immunopharma Inc For: 27 July By Investing.com

This article reports on a Form 4 filing for Lyell Immunopharma Inc. dated July 27. It includes the stock symbol LYEL and its performance for the day. The article appears to be a brief financial news update from Investing.com.

Immutep Ltd (IMMP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article for Immutep Ltd (IMMP) concerns the company's revenue breakdown by business segments and regional contributions. However, it explicitly states that the relevant data for these breakdowns has not been disclosed by the company yet. Therefore, the article provides no specific financial details …

Altimmune Scores Alcohol Use Disorder Win As Lilly, Novo Circle Same Indication

Altimmune has achieved a significant milestone in treating alcohol use disorder, a field also being explored by major pharmaceutical companies like Eli Lilly and Novo Nordisk. The article highlights Altimmune's efforts to innovate the treatment paradigm for this condition.

IMMR Maintained by BWS Financial -- Price Target Stays at $13.50

Immersion Corporation (IMMR) has had its "Buy" rating and $13.50 price target maintained by BWS Financial, despite a current trading price of $7.66. While insider activity shows net selling and the stock's P/E ratio is significantly higher than its historical median, analysts see considerable …

Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial

Altimmune's experimental GLP-1 drug, pemvidutide, significantly reduced heavy drinking days in a Phase 2 trial for alcohol use disorder. The drug, which targets both GLP-1 and glucagon receptors, also aims to treat the fatty liver disease MASH and showed a robust clinical profile compared …

BlackRock, Inc. (NYSE: BLK) discloses 6.7% ownership in Immuneering Corp (IMRX)

BlackRock, Inc. has disclosed a 6.7% ownership stake in Immuneering Corp (IMRX), as reported in a Schedule 13G SEC filing. This position amounts to 4,356,235 shares of Immuneering’s Class A stock as of June 30, 2026. BlackRock holds sole voting power over 4,314,766 shares …

Shimmick Corporation to Announce Second Quarter 2026 Financial Results on August 10, 2026

Shimmick Corporation (Nasdaq: SHIM) announced it will release its second quarter 2026 financial results after market close on Monday, August 10, 2026. The company will also host a video webcast conference call on the same day at 4:30 p.m. Eastern Time to discuss these …

Zimmer Biomet Shares Rise After UBS Upgrade

Zimmer Biomet shares experienced a rise after UBS upgraded the company's stock. This upgrade by UBS indicates a more positive outlook on Zimmer Biomet's financial prospects and market position.

ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by ImmunityBio, Inc. (NASDAQ:IBRX). The firm is encouraging investors who purchased ImmunityBio securities before January 19, 2026, and still hold them, to contact them to assist with the investigation. The investigation …

Zimmer upgraded to Buy from Sell at UBS on growth and innovation

[Zimmer Biomet office in Mississauga, Ontario, Canada.] JHVEPhoto/iStock Editorial via Getty Images Zimmer Biomet (ZBH [https://seekingalpha.com/symbol/ZBH]) traded higher on Tuesday after UBS analyst Patrick Wood assumed its coverage and upgraded the stock to Buy from Sell, citing the orthopedic product maker’s growth prospects and …

Shimmick Corp (SHIM) Institutional Confidence

This article analyzes Shimmick Corp's (SHIM) institutional confidence score, which is currently 3.00, ranking 32 out of 41 in its industry. The institutional shareholding proportion has increased by 51.12% quarter-over-quarter, with prominent investors like James Simons holding a significant stake. The report also details …

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – MUN:6YG

This article provides a revenue breakdown for Immunocore Holdings Plc (MUN:6YG). Last year, the company generated €340.58 million, with the Immunotherapies segment contributing the entire amount. The United States was the primary geographic contributor, accounting for €218.81 million of the total revenue.

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

Altimmune announced positive top-line results from its RECLAIM Phase 2 trial for pemvidutide, showing significant reductions in heavy drinking days and improvements across secondary endpoints for alcohol use disorder. The drug also achieved significant body weight reduction and demonstrated a favorable tolerability profile. Altimmune …

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

Altimmune's experimental drug pemvidutide successfully met its primary endpoint in a Phase II trial for alcohol use disorder (AUD), significantly reducing heavy drinking days and improving other key measures. The company plans to seek an FDA end-of-Phase-II meeting to discuss moving towards a Phase …

Immunovant, Inc. Revenue Breakdown – NASDAQ:IMVT

This page provides financial overview for Immunovant, Inc. (NASDAQ: IMVT). It indicates that the market is closed with no trades. The article is primarily a navigation and information hub for financial data on Immunovant, Inc., mentioning sections like "Fundamentals and stats," "Overview," "Statements," "Statistics," …

Shimmick sets 4:30 p.m. webcast for Q2 results Aug. 10

Shimmick Corporation (Nasdaq: SHIM) announced it will release its second quarter 2026 financial results after market close on Monday, August 10, 2026. The company will host a video webcast conference call to discuss the results at 4:30 p.m. Eastern Time on the same day. …

Trending Industry Today: Bitmine Immersion Technologies Leads Losses In ETH-Holding Companies Stocks

This article identifies Bitmine Immersion Technologies as the leading decliner among ETH-holding companies today. The stock's current performance is significantly underperforming compared to its peers in the digital assets industry. Data indicates a noticeable drop in its daily trading, making it a focal point …

ALT Stock Holds Range As Traders Weigh Cash And Losses

Altimmune Inc. (ALT) stock is consolidating between $2.75 and $3.05 after recent selling pressure, despite a 12.16% surge driven by clinical trial progress. The company boasts a strong balance sheet with $331.5M in cash, providing a long funding runway, but continues to post significant …

ALT Stock Holds Range As Cash Runway Supports Speculative Trading

Altimmune Inc. (ALT) stock has been trading up by 11.82%, primarily driven by promising clinical trial progress. Despite recent sideways trading between $2.75 and $3.15, the company has a strong balance sheet with $97.6M in cash and minimal debt, providing a significant runway despite …

Altimmune rises as GLP-1 cuts drinking in mid-stage trial

Altimmune (ALT) shares rose over 15% in premarket trading after its GLP-1 candidate, pemvidutide, demonstrated a reduction in drinking in a mid-stage trial for patients with alcohol use disorder. The biotech company, headquartered in Gaithersburg, Maryland, released topline data from the study.

UBS initiates Zimmer Biomet stock coverage with buy rating By Investing.com

UBS has initiated coverage on Zimmer Biomet Holdings Inc. (NYSE:ZBH) with a "buy" rating and a price target of $115, citing the company's sales force restructuring and its Monogram autonomous robot as key drivers for future growth. The investment bank anticipates significant upside potential …

Scinai Immunotherapeutics Ltd

The article provides a revenue breakdown for Scinai Immunotherapeutics Ltd (SCNI), noting that relevant data for business segments and regional revenue and profit contribution have not yet been disclosed by the company. It briefly shows the current stock price, change, market cap, and indicates …

Altimmune reports positive Phase 2 RECLAIM topline results for pemvidutide in AUD

Altimmune announced positive topline Phase 2 results for its drug pemvidutide 2.4 mg in treating Alcohol Use Disorder (AUD), demonstrating a significant reduction in heavy drinking days compared to placebo. The RECLAIM study met its primary endpoint and two FDA-recognized secondary endpoints, showing favorable …

Altimmune stock surges 18% on positive trial results

Altimmune Inc. (NASDAQ:ALT) shares surged 18% after the company announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The trial met its primary and key secondary endpoints, showing a statistically significant reduction in heavy drinking days and …

ImmuCell Corp (ICCC) Income Statement

This article provides a detailed quarterly and annual income statement for ImmuCell Corp (ICCC), covering various financial metrics from total revenue to diluted earnings per share. It offers insights into the company's financial performance and operational efficiency over several fiscal years and quarters. The …

1 Popular Cryptocurrency to Buy Before It Soars 13,000%, According to Bitmine's Tom Lee

Cryptocurrencies have had a rough time since October 2025, with most major coins and tokens trading deeply in the red. Not even the industry leaders have escaped the carnage, with Ethereum's native cryptocurrency, Ether (CRYPTO: ETH), down more than 60% from its all-time high. …

Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by First Trust Advisors LP

First Trust Advisors LP increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 23.2% in the first quarter, now owning 387,537 shares valued at over $35 million. Several other hedge funds also adjusted their holdings, with institutional investors collectively owning 88.89% of the …

Gabelli Funds LLC Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Gabelli Funds LLC significantly increased its stake in Zimmer Biomet Holdings, Inc. by 13% in the first quarter, bringing its total holdings to 147,350 shares valued at $13.3 million. Despite a generally cautious analyst outlook, Zimmer Biomet reported strong quarterly earnings, beating estimates with …